Ubs Oconnor LLC Context Therapeutics Inc. Transaction History
Ubs Oconnor LLC
- $1.72 Billion
- Q2 2024
A detailed history of Ubs Oconnor LLC transactions in Context Therapeutics Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 293,758 shares of CNTX stock, worth $546,389. This represents 0.03% of its overall portfolio holdings.
Number of Shares
293,758Holding current value
$546,389% of portfolio
0.03%Shares
4 transactions
Others Institutions Holding CNTX
# of Institutions
37Shares Held
57.2MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT7.42MShares$13.8 Million3.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.42MShares$13.8 Million0.49% of portfolio
-
Avidity Partners Management LP Dallas, TX7.42MShares$13.8 Million0.73% of portfolio
-
Nextech Invest Ag7.42MShares$13.8 Million2.8% of portfolio
-
Blue Owl Capital Holdings LP New York, NY5.16MShares$9.6 Million4.29% of portfolio
About Context Therapeutics Inc.
- Ticker CNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,966,100
- Market Cap $29.7M
- Description
- Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therape...